Dihydroergotamine Mesylate NDC 70069-880

NDC codes

FDA NDC Directory

Product NDC (as listed)70069-880Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70069-0880Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70069-880-08	70069088008	8 CARTON in 1 KIT (70069-880-08) / 1 VIAL in 1 CARTON (70069-880-01) / 1 mL in 1 VIALMarketed from Mar 24, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Dihydroergotamine Mesylate
Generic name (nonproprietary): dihydroergotamine mesylate
Active ingredients: Dihydroergotamine mesylate — 4 mg/mL
Dosage form: Spray, Metered
Route: Nasal
Labeler: Somerset Therapeutics, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215228
Marketing start: Mar 24, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Ergotamines (Chemical structure)
Identifiers: Product ID 70069-880_8d88a6e3-0b91-4414-acce-4de8bb371ac1SPL ID 8d88a6e3-0b91-4414-acce-4de8bb371ac1SPL set ID c8ffdc19-a90d-453c-b094-2347e116b405RxCUI 861668UNII 81AXN7R2QTUPC 0370069880081
Pharmacologic class: Ergotamine Derivative

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Nasal products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470069088008 followed by a unit qualifier and the quantity

Package 70069-0880-08. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 24, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Dihydroergotamine mesylate nasal spray is indicated for the acute treatment of migraine headaches with or without aura. Dihydroergotamine mesylate nasal spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)